PMID: 12777082Jun 5, 2003Paper

Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma

Journal of Neuro-oncology
Andrea SalmaggiAmerigo Boiardi

Abstract

Intracavitary levels of VEGF, bFGF, IL-8 and IL- 12 were evaluated by ELISA in 45 patients, 7 with recurrent anaplastic astrocytoma (rAA), 12 with glioblastoma (GBM) and 26 with recurrent glioblastoma (rGBM). In 25 patients plasma levels of the molecules were also quantitated. Twenty-three healthy controls were also studied for plasma concentrations of the same molecules. Plasma levels of VEGF (mean 33.89 +/- 6.71 pg/ml) and bFGF (mean 11.1 +/- 3.24 pg/ml) were higher in patients than in controls (mean 16.78 +/- 3.7 pg/ml for VEGF, mean 0.21 +/- 0.09 pg/ml for bFGF) (p = 0.04 and p = 0.001, respectively) while plasma IL-12 levels were lower (mean 45.6 +/- 1.5 pg/ml in patients, mean 79.7 +/- 1.3 pg/ml in controls) (p = 0.009). Intracavitary VEGF levels were 5-53.307 fold higher (mean 90,900 +/- 24,789 pg/ml) than in the corresponding plasma. Also IL-8 concentrations were higher in intracavitary fluid (mean 6,349.76 +/- 1,460.93 pg/ml) than in plasma (mean 43.44 +/- 24.82 pg/ml). Maximum VEGF levels were found in tumor fluid of recurrent glioblastoma patients (mean 147,678 +/- 39.903 pg/ml), intermediate levels in glioblastoma patients (mean 20,322 +/- 11,892 pg/ml) and lower levels in rAA patients (mean 9,111 +/- 5,789 pg/ml). ...Continue Reading

Citations

Jan 28, 2005·Journal of Neuro-oncology·Balveen KaurErwin G Van Meir
Apr 7, 2009·Expert Opinion on Biological Therapy·Jenia Jenab-Wolcott, Bruce J Giantonio
Sep 18, 2012·BMC Medical Genomics·Elodie VauléonMarc Aubry
Aug 21, 2013·Expert Review of Neurotherapeutics·Sajeel Chowdhary, Marc Chamberlain
Apr 25, 2014·Cellular and Molecular Life Sciences : CMLS·Mario VallonCalvin J Kuo
Feb 7, 2018·Therapeutic Advances in Neurological Disorders·Jennifer JeckLars Bullinger
Jul 30, 2019·Expert Opinion on Investigational Drugs·Casey AnthonyDavid Cory Adamson
Feb 8, 2008·Current Treatment Options in Oncology·David A ReardonJames J Vredenburgh
May 13, 2008·Human Gene Therapy·Duane A MitchellJohn H Sampson
May 13, 2008·Expert Review of Anticancer Therapy·Lynn Feun, Niramol Savaraj
May 24, 2011·Clinical Medicine Insights. Oncology·Marc C Chamberlain
Jun 6, 2012·Expert Opinion on Biological Therapy·Mustafa KhasrawChristian Grommes
Jun 21, 2014·Future Oncology·Alba A BrandesAntoine F Carpentier
Mar 25, 2014·Expert Opinion on Biological Therapy·Mustafa KhasrawChristian Grommes
Feb 11, 2014·Current Oncology Reports·John F de Groot, Jacob J Mandel
Aug 8, 2014·Frontiers in Oncology·Graeme F WoodworthHenry Brem
Nov 23, 2016·The Journal of Cell Biology·Sandra ScharawRainer Pepperkok
Jul 24, 2007·Nature Reviews. Neuroscience·Rakesh K JainTracy T Batchelor
Oct 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James J VredenburghHenry S Friedman
Dec 15, 2010·Journal of Neurosurgery·Aaron J ClarkManish K Aghi
Oct 12, 2011·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Andrea SalmaggiAntonio Silvani
Jun 2, 2012·Expert Opinion on Drug Discovery·David A ReardonWolfgang Wick
Jan 7, 2016·Cancer Investigation·Marianne LabussièreMarc Sanson
Dec 2, 2014·Neurosurgical Focus·Darryl LauManish K Aghi
Mar 21, 2013·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Yasushi SodaInder M Verma
Apr 24, 2015·CNS Oncology·Ashley Ghiaseddin, Katherine B Peters

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Astrocytes

Astrocytes are glial cells that support the blood-brain barrier, facilitate neurotransmission, provide nutrients to neurons, and help repair damaged nervous tissues. Here is the latest research.